These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 28617920)

  • 1. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
    Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
    JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang ZX; Wu HX; Xie L; Wang YN; Yang LP; He MM; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    JAMA Netw Open; 2019 May; 2(5):e193433. PubMed ID: 31050784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
    Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK
    JAMA Oncol; 2018 Apr; 4(4):522-528. PubMed ID: 29470579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
    Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
    J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Zhang S; Li S; Cui Y; Zhao P; Sun X; Cheng Y
    Front Oncol; 2021; 11():696010. PubMed ID: 34336683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
    Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
    JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
    J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
    Li X; Wang H; Lin W; Xu Q
    Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials.
    Li LX; Socinski MA; Kichenadasse G; Karapetis CS; Shahnam A; McKinnon RA; Rowland A; Hopkins AM; Sorich MJ
    BMC Cancer; 2024 Mar; 24(1):379. PubMed ID: 38528478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L
    Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
    Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
    Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
    Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.
    Blumenthal GM; Gong Y; Kehl K; Mishra-Kalyani P; Goldberg KB; Khozin S; Kluetz PG; Oxnard GR; Pazdur R
    Ann Oncol; 2019 May; 30(5):830-838. PubMed ID: 30796424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.
    Chaunzwa TL; Qian JM; Li Q; Ricciuti B; Nuernberg L; Johnson JW; Weiss J; Zhang Z; MacKay J; Kagiampakis I; Bikiel D; Di Federico A; Alessi JV; Mak RH; Jacob E; Awad MM; Aerts HJWL
    JAMA Oncol; 2024 Jun; 10(6):773-783. PubMed ID: 38780929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.